× Industry Reports Services Press Release Contact us About us

Asia Pacific Antiviral Drugs Market By Type (Branded, Generic), By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors), By Indication (Influenza, HIV AIDS, Hepatitis, Herpes Simplex Virus [HSV], Coronavirus Infection), By Age Group (Pediatric, Adult, Geriatric), Research Report, Country Outlook (Japan, China, India, Australia, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines) Price Trends, Growth Prospects, Competitive Industry Share & Forecasts, 2021 - 2027
Published Date: March 2021 | Publisher: Graphical Research Report ID: GR1738 | Delivery : PDF  Request Free Sample

Report Content

Chapter 1   Methodology

1.1    Market definitions

1.2    Forecast assumptions

1.3    Data sources

1.3.1    Secondary

1.3.1.1    Paid sources

1.3.1.2    Unpaid sources

1.3.2    Primary

Chapter 2   Market Summary

2.1    Asia Pacific anti-viral drugs industry summary, 2016 – 2027

2.1.1    Country trends

2.1.2    Drug class trends

2.1.3    Indication trends

2.1.4    Type trends

2.1.5    Age group trends

Chapter 3   Market Analysis

3.1    Industry segmentation

3.2    Industry outlook, 2016 – 2027 (USD Million)

3.3    Major factor analysis

3.3.1    Drivers

3.3.1.1    Increasing prevalence of viral infections including COVID-19

3.3.1.2    Presence of pipeline products for HIV treatment

3.3.1.3    Increasing geriatric population

3.3.2    Industry pitfalls & challenges

3.3.2.1    Presence of generics

3.3.2.2    Rising awareness about preventive drugs treatment

3.3.2.3    Drug resistance

3.3.2.4    High cost of HIV and Hepatitis drug treatment

3.4    Analysis of COVID-19 impact on the industry

3.5    Porter’s analysis

3.6    Competitive review, 2020

3.7    PEST analysis

Chapter 4   Asia Pacific Anti-viral Drugs Market, By Drug Class

4.1    Market trends

4.2    DNA polymerase inhibitors

4.2.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

4.3    Reverse transcriptase inhibitors

4.3.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

4.4    Protease inhibitors

4.4.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

4.5    Neuraminidase inhibitors

4.5.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

4.6    Others

4.6.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

Chapter 5   Asia Pacific Anti-viral Drugs Market, By Indication

5.1    Market trends

5.2    Influenza

5.2.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

5.3    HIV/AIDS

5.3.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

5.4    Hepatitis

5.4.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

5.5    Herpes Simplex Virus

5.5.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

5.6    Coronavirus Infection

5.6.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

5.7    Others

5.7.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

Chapter 6   Asia Pacific Anti-viral Drugs Market, By Type

6.1    Market trends

6.2    Branded

6.2.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

6.3    Generic

6.3.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

Chapter 7   Asia Pacific Anti-viral Drugs Market, By Age Group

7.1    Market trends

7.2    Adult

7.2.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

7.3    Pediatric

7.3.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

7.4    Geriatric

7.4.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

Chapter 8   Asia Pacific Anti-viral Drugs Market, By Country

8.1    Market trends

8.2    Japan

8.2.1    Market estimates and forecast, by drug class, 2016 – 2027 (USD Million)

8.2.2    Market estimates and forecast, by indication, 2016 – 2027 (USD Million)

8.2.3    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

8.2.4    Market estimates and forecast, by age group, 2016 – 2027 (USD Million)

8.3    China

8.3.1    Market estimates and forecast, by drug class, 2016 – 2027 (USD Million)

8.3.2    Market estimates and forecast, by indication, 2016 – 2027 (USD Million)

8.3.3    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

8.3.4    Market estimates and forecast, by age group, 2016 – 2027 (USD Million)

8.4    India

8.4.1    Market estimates and forecast, by drug class, 2016 – 2027 (USD Million)

8.4.2    Market estimates and forecast, by indication, 2016 – 2027 (USD Million)

8.4.3    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

8.4.4    Market estimates and forecast, by age group, 2016 – 2027 (USD Million)

8.5    Australia

8.5.1    Market estimates and forecast, by drug class, 2016 – 2027 (USD Million)

8.5.2    Market estimates and forecast, by indication, 2016 – 2027 (USD Million)

8.5.3    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

8.5.4    Market estimates and forecast, by age group, 2016 – 2027 (USD Million)

8.6    South Korea

8.6.1    Market estimates and forecast, by drug class, 2016 – 2027 (USD Million)

8.6.2    Market estimates and forecast, by indication, 2016 – 2027 (USD Million)

8.6.3    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

8.6.4    Market estimates and forecast, by age group, 2016 – 2027 (USD Million)

8.7    Singapore

8.7.1    Market estimates and forecast, by drug class, 2016 – 2027 (USD Million)

8.7.2    Market estimates and forecast, by indication, 2016 – 2027 (USD Million)

8.7.3    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

8.7.4    Market estimates and forecast, by age group, 2016 – 2027 (USD Million)

8.8    Indonesia

8.8.1    Market estimates and forecast, by drug class, 2016 – 2027 (USD Million)

8.8.2    Market estimates and forecast, by indication, 2016 – 2027 (USD Million)

8.8.3    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

8.8.4    Market estimates and forecast, by age group, 2016 – 2027 (USD Million)

8.9    Thailand

8.9.1    Market estimates and forecast, by drug class, 2016 – 2027 (USD Million)

8.9.2    Market estimates and forecast, by indication, 2016 – 2027 (USD Million)

8.9.3    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

8.9.4    Market estimates and forecast, by age group, 2016 – 2027 (USD Million)

8.10    Malaysia

8.10.1    Market estimates and forecast, by drug class, 2016 – 2027 (USD Million)

8.10.2    Market estimates and forecast, by indication, 2016 – 2027 (USD Million)

8.10.3    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

8.10.4    Market estimates and forecast, by age group, 2016 – 2027 (USD Million)

8.11    Philippines

8.11.1    Market estimates and forecast, by drug class, 2016 – 2027 (USD Million)

8.11.2    Market estimates and forecast, by indication, 2016 – 2027 (USD Million)

8.11.3    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

8.11.4    Market estimates and forecast, by age group, 2016 – 2027 (USD Million)

Chapter 9   Company Profiles

9.1    Gilead Sciences, Inc

9.1.1    Business overview

9.1.2    Financial data

9.1.3    Product landscape

9.1.4    Strategic outlook

9.2    Johnson & Johnson

9.2.1    Business overview

9.2.2    Financial data

9.2.3    Product landscape

9.2.4    Strategic outlook

9.3    GlaxoSmithKline

9.3.1    Business overview

9.3.2    Financial data

9.3.3    Product landscape

9.3.4    Strategic outlook

9.4    AbbVie Inc.

9.4.1    Business overview

9.4.2    Financial data

9.4.3    Product landscape

9.4.4    Strategic outlook

9.5    Merck & Co.

9.5.1    Business overview

9.5.2    Financial data

9.5.3    Product landscape

9.5.4    Strategic outlook

9.6    Bristol Myers Squibb

9.6.1    Business overview

9.6.2    Financial data

9.6.3    Product landscape

9.6.4    Strategic outlook

9.7    Aurobindo Pharma Ltd.

9.7.1    Business overview

9.7.2    Financial data

9.7.3    Product landscape

9.7.4    Strategic outlook

9.8    Cipla Inc.

9.8.1    Business overview

9.8.2    Financial data

9.8.3    Product landscape

9.8.4    Strategic outlook

9.9    Sun Pharmaceutical Industries Ltd

9.9.1    Business overview

9.9.2    Financial data

9.9.3    Product landscape

9.9.4    Strategic outlook

9.10    Viatris Inc.

9.10.1    Business overview

9.10.2    Financial data

9.10.3    Product landscape

9.10.4    Strategic outlook
 


Premium Report

Have questions?
  • Inquire Before Buying
  • Why Choose us?

    • on-time delivery On-Time Delivery

      We commit to on-time delivery of reports to keep you ahead.

    • assured quality Assured Quility

      With a wide network of industry experts and trained in-house analysts, we assure best service quality.

    • Custom Research Service

      We offer research services to meet specific client requirements and provide them with actionable insights on target markets.

    • payment security Payment Security

      Our safe payment gateway gives you full control of your personal data, at all times.

    Connect with our sales team

     1-800-986-6917

     [email protected]